CN115300605A - Probiotic powder for resisting obesity and losing weight and application thereof - Google Patents
Probiotic powder for resisting obesity and losing weight and application thereof Download PDFInfo
- Publication number
- CN115300605A CN115300605A CN202210980670.9A CN202210980670A CN115300605A CN 115300605 A CN115300605 A CN 115300605A CN 202210980670 A CN202210980670 A CN 202210980670A CN 115300605 A CN115300605 A CN 115300605A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- bag
- probiotic powder
- powder
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a probiotic powder for resisting obesity and losing weight and application thereof, belonging to the technical field of microorganisms and the technical field of medicines. The probiotic powder consists of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041, lactobacillus acidophilus AD031, dual prebiotics, vitamins, iron and collagen peptide; can solve multiple problems of obese people, and is specifically embodied as follows: the probiotic powder has the effects of resisting obesity, reducing weight, protecting cartilage tissue of joints, resisting oxidation, tightening skin, and making skin glossy. Therefore, the probiotic powder containing bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041 and lactobacillus acidophilus AD031 has great application prospect in promoting the anti-obesity and slimming performance of human bodies.
Description
Technical Field
The invention relates to a probiotic powder for resisting obesity and losing weight and application thereof, belonging to the technical field of microorganisms and the technical field of medicines.
Background
With the progress of society and the improvement of living standard of people, the phenomenon of obesity is seen everywhere in life. Whether male or female, whether age, the excessive intake of food or the change of body metabolism lead to the excessive accumulation of fat in the body, which leads to the excessive weight increase and causes pathological, physiological changes or latent phenomena in the body.
Obesity not only affects the beauty of the body, but also brings inconvenience to life. If not noticed, other complications may also be caused, such as joint soft tissue injury, non-alcoholic fatty liver disease, diabetes, hyperlipidemia, hypertension, etc.
Aiming at different problem manifestations of obese people, the main clinical treatment methods are surgical gastric resection, enema weight reduction and medication taking, and exercise-assisted treatment is also available, but long-term medication may cause drug obesity, which results in poor treatment effect and other pathological changes.
Disclosure of Invention
In order to solve various problems of obese people, such as slow metabolic digestion, cartilage tissue damage during body building and exercise, skin aging, dullness and other expressions, according to the finding results of the existing clinic and researchers, the probiotic powder for resisting obesity and slimming and the application thereof are provided, and the probiotic powder specifically comprises the following components:
the invention provides a probiotic powder for resisting obesity and slimming, which consists of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041, lactobacillus acidophilus AD031, dual prebiotics, vitamins, iron and collagen peptide; the bifidobacterium bifidum BGN4, the bifidobacterium longum BORI, the lactobacillus casei IBS041 and the lactobacillus acidophilus AD031 are main regulating components, and the dual prebiotics, the vitamins, the iron and the collagen peptide are auxiliary regulating components; wherein: the dual prebiotics comprise isomaltooligosaccharide and fructo-oligosaccharide, and the vitamins comprise vitamin A, vitamin B1, vitamin B6, vitamin B2, nicotinic acid, vitamin B12, vitamin E, folic acid and vitamin C.
In one embodiment of the present invention, the probiotic powder may be added in an amount of 5g per bag as follows:
bifidobacterium bifidum BGN4 50 hundred million CFU/bag (counting live bacteria)
Bifidobacterium longum BORI 25 hundred million CFU/bag (in terms of viable count)
Lactobacillus casei IBS041 30 hundred million CFU/bag (counted by viable count)
Lactobacillus acidophilus AD031 25 hundred million CFU/bag (counting according to viable count)
Isomaltose hypgather 5 mg/bag
Fructo-oligosaccharide 8.2 mg/bag
Vitamin A34 mug/bag
Vitamin B1 0.044 mg/bag
Vitamin B6 0.044 mg/bag
Vitamin B2 0.044 mg/bag
Nicotinic acid 0.66 mg/bag
Vitamin B12 0.132 mug/bag
Vitamin E0.36 mg/bag
Folic acid 12 mu g/bag
Vitamin C4.5 mg/bag
Iron 0.44 mg/bag
Collagen peptide 2.5 g/bag
In an embodiment of the present invention, a method for preparing lyophilized powder of probiotic bacteria comprises the following steps:
1) Respectively marking bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041 and lactobacillus acidophilus AD031 on MRS solid culture medium, and culturing for 48h at 37 ℃ to obtain single bacterial colony.
2) Selecting single colonies, respectively inoculating the single colonies in an MRS liquid culture medium, and culturing for 24-48 h at 37 ℃ for activation to obtain first-level seed liquid.
3) Respectively transferring the primary seed liquid into a seed culture medium according to the inoculation amount of 3% (v/v) to obtain a secondary seed liquid, and culturing for 24-48 h under the culture condition of 37 ℃.
4) And respectively inoculating the secondary seed liquid into a fermentation culture medium for high-density fermentation, wherein the inoculation amount is 3% (v/v), the culture condition is 35-37 ℃, and the culture is carried out for 24-48 h.
5) When the density of the thallus in the fermentation liquid reaches 10 8 ～10 9 CFU/mL, respectively collecting fermentation liquor; and respectively centrifuging the fermentation liquor to collect thalli.
6) And after the thalli are collected, respectively using a freeze-drying protective agent to carry out heavy suspension to obtain heavy suspensions.
7) Freeze-drying the heavy suspension by vacuum freezing method to obtain freeze-dried bacterial powder of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041 and lactobacillus acidophilus AD 031.
In one embodiment of the present invention, the medium is MRS medium: 10g of peptone, 10g of beef extract powder, 20g of glucose, 2g of sodium acetate, 5g of yeast extract powder, 2g of diammonium hydrogen citrate and K 2 PO 4 ·3H 2 O 0.4g、MgSO 4 ·7H 2 O 0.2g、MnSO 4 0.05g, 1mL of Tween 80 and 15g of agar, and adjusting the pH value to 6.2-6.3.
In one embodiment of the invention, the lyoprotectant is prepared from the following components in percentage by weight: 15% of skimmed milk powder, 6% of trehalose, 4% of glycerol and 1.5% of xylitol.
In an embodiment of the present invention, the preparation method of the probiotic powder comprises the following steps:
1) Respectively taking 50 hundred million CFU of freeze-dried powder of bifidobacterium bifidum BGN4, 25 hundred million CFU of freeze-dried powder of bifidobacterium longum BORI, 30 hundred million CFU of freeze-dried powder of lactobacillus casei IBS041 and 25 hundred million CFU of freeze-dried powder of lactobacillus acidophilus AD031, and mixing.
2) Sequentially adding 5mg of isomaltooligosaccharide, 8.2mg of fructo-oligosaccharide, 34 μ g of vitamin A, 0.044mg of vitamin B, 6.044 mg of vitamin B, 0.044mg of vitamin B2, 0.044mg of nicotinic acid, 0.132 μ g of vitamin B, 0.36mg of vitamin E, 12 μ g of folic acid, 4.5mg of vitamin C, 0.44mg of ferrum and 2.5g of collagen peptide into the probiotic freeze-dried powder mixture, uniformly stirring, fully mixing, and subpackaging into bags to obtain the probiotic powder, wherein the bags are made of a food-grade PE packaging material with good sealing performance and safety, and the specification is 5g.
In an embodiment of the present invention, the probiotic powder is used in an amount of:
the probiotic powder is suitable for both obese and fitness people. The edible suggestion is as follows: the food is taken twice a day, and is drunk after being mixed with water at a temperature lower than 37 deg.C or directly taken within half an hour after meal.
If the antibiotics are taken, the antibiotics are recommended to be taken firstly, and then the probiotic powder is taken at intervals of 2-3 hours.
The invention also provides application of the anti-obesity and slimming probiotic powder in anti-obesity and slimming performances.
The invention has the beneficial effects that:
1) The invention provides an anti-obesity and slimming probiotic powder and application thereof, wherein the probiotic powder consists of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041, lactobacillus acidophilus AD031, dual prebiotics, vitamins, iron and collagen peptide; can solve various problems of obese people, and is specifically embodied as follows: the probiotic powder has the effects of resisting obesity, reducing weight, protecting cartilage tissue of joints, resisting oxidation, tightening skin, and making skin glossy. Therefore, the probiotic powder containing bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041 and lactobacillus acidophilus AD031 has great application prospect in promoting the anti-obesity and slimming performance of human bodies.
2) In the invention, bifidobacterium bifidum BGN4 and bifidobacterium longum BORI are separated from the excrement of healthy breast-fed infants, lactobacillus casei IBS041 is separated from healthy human intestinal tracts and excrement, and lactobacillus acidophilus AD031 is secreted from healthy human intestinal tracts. The collagen peptide is derived from fish collagen peptide, and double prebiotics, vitamins and iron are added in a matching way, so that the addition amount of the collagen peptide is in accordance with national GB/T29602-2013 and GB 14880-2012. Therefore, the probiotic powder is healthy and has no toxic or side effect on human bodies.
Detailed Description
The invention provides a probiotic powder for resisting obesity and slimming, which consists of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041, lactobacillus acidophilus AD031, dual prebiotics, vitamins, iron and collagen peptide; the bifidobacterium bifidum BGN4, the bifidobacterium longum BORI, the lactobacillus casei IBS041 and the lactobacillus acidophilus AD031 are main regulating components, and the dual prebiotics, the vitamins, the iron and the collagen peptide are auxiliary regulating components; wherein: the dual prebiotics comprise isomaltooligosaccharide and fructo-oligosaccharide, and the vitamins comprise vitamin A, vitamin B1, vitamin B6, vitamin B2, nicotinic acid, vitamin B12, vitamin E, folic acid and vitamin C.
The following further describes embodiments of the present invention. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
The media involved in the following examples are as follows:
MRS culture medium: 10g of peptone, 10g of beef extract powder, 20g of glucose, 2g of sodium acetate, 5g of yeast extract powder, 2g of diammonium hydrogen citrate and K 2 PO 4 ·3H 2 O 0.4g、MgSO 4 ·7H 2 O 0.2g、MnSO 4 0.05g, 1mL of Tween 80 and 15g of agar, and adjusting the pH value to 6.2-6.3.
Example 1 preparation of lyophilized powder of Bifidobacterium bifidum BGN4
1) Bifidobacterium bifidum BGN4 is streaked on MRS solid culture medium and cultured for 48h at 37 ℃ to obtain single colony.
2) Selecting a single colony, inoculating the single colony in an MRS liquid culture medium, and culturing for 24-48 h at 37 ℃ for activation to obtain first-level seed liquid.
3) Respectively transferring the primary seed liquid into a seed culture medium according to the inoculation amount of 3% (v/v) to obtain a secondary seed liquid, and culturing for 24-48 h under the culture condition of 37 ℃.
4) And respectively inoculating the secondary seed liquid into a fermentation culture medium for high-density fermentation, wherein the inoculation amount is 3% (v/v), the culture condition is 35-37 ℃, and the culture is carried out for 24-48 h.
5) When the density of the thallus in the fermentation liquid reaches 10 8 ～10 9 CFU/mL, respectively collecting fermentation liquor; and respectively centrifuging the fermentation liquor to collect thalli.
6) After the thalli are collected, the thalli are resuspended by using a freeze-drying protective agent (the freeze-drying protective agent is prepared from the following components in percentage by weight: skimmed milk powder 15%, trehalose 6%, glycerol 4% and xylitol 1.5%) to obtain a resuspension.
7) And (3) freeze-drying the heavy suspension by adopting a vacuum freezing method to obtain bifidobacterium bifidum BGN4 freeze-dried powder.
EXAMPLE 2 preparation of lyophilized powder of Bifidobacterium longum BORI
1) The Bifidobacterium longum BORI is streaked on MRS solid culture medium, and cultured for 48h at 37 ℃ to obtain single colony.
2) Selecting a single colony, inoculating the single colony in an MRS liquid culture medium, and culturing for 24-48 h at 37 ℃ for activation to obtain a first-level seed solution.
3) Respectively transferring the primary seed liquid into a seed culture medium according to the inoculation amount of 3% (v/v) to obtain a secondary seed liquid, and culturing for 24-48 h under the culture condition of 37 ℃.
4) And respectively inoculating the secondary seed liquid into a fermentation culture medium for high-density fermentation, wherein the inoculation amount is 3% (v/v), the culture condition is 35-37 ℃, and the culture is carried out for 24-48 h.
5) When the density of thalli in the fermentation solution reaches 10 8 ～10 9 CFU/mL, respectively collecting fermentation liquor; and respectively centrifuging the fermentation liquor to collect thalli.
6) And (3) collecting the thallus, and then re-suspending the thallus by using a freeze-drying protective agent (the freeze-drying protective agent is prepared from the following components in percentage by weight: skimmed milk powder 15%, trehalose 6%, glycerol 4% and xylitol 1.5%) to obtain a resuspension.
7) And (3) freeze-drying the heavy suspension by adopting a vacuum freezing method to obtain bifidobacterium longum BORI freeze-dried powder.
EXAMPLE 3 preparation of Lactobacillus casei IBS041 lyophilized powder
1) Lactobacillus casei IBS041 is streaked on an MRS solid culture medium and cultured for 48h under the condition of 37 ℃ to obtain a single colony.
2) Selecting a single colony, inoculating the single colony in an MRS liquid culture medium, and culturing for 24-48 h at 37 ℃ for activation to obtain a first-level seed solution.
3) Respectively transferring the first-stage seed liquid into a seed culture medium according to the inoculation amount of 3% (v/v) to obtain a second-stage seed liquid, and culturing for 24-48 h under the culture condition of 37 ℃.
4) And respectively inoculating the secondary seed liquid into a fermentation culture medium for high-density fermentation, wherein the inoculation amount is 3% (v/v), the culture condition is 35-37 ℃, and the culture is carried out for 24-48 h.
5) When the density of thalli in the fermentation solution reaches 10 8 ～10 9 CFU/mL, respectively collecting fermentation liquor; and respectively centrifuging the fermentation liquor to collect thalli.
6) After the thalli are collected, the thalli are resuspended by using a freeze-drying protective agent (the freeze-drying protective agent is prepared from the following components in percentage by weight: skimmed milk powder 15%, trehalose 6%, glycerol 4% and xylitol 1.5%) to give a resuspension.
7) And (4) freeze-drying the heavy suspension by adopting a vacuum freezing method to obtain lactobacillus casei IBS041 freeze-dried powder.
Example 4: preparation of lactobacillus acidophilus AD031 freeze-dried powder
1) Lactobacillus acidophilus AD031 is streaked on MRS solid culture medium, and cultured for 48h at 37 deg.C to obtain single colony.
2) Selecting a single colony, inoculating the single colony in an MRS liquid culture medium, and culturing for 24-48 h at 37 ℃ for activation to obtain a first-level seed solution.
3) Respectively transferring the first-stage seed liquid into a seed culture medium according to the inoculation amount of 3% (v/v) to obtain a second-stage seed liquid, and culturing for 24-48 h under the culture condition of 37 ℃.
4) And respectively inoculating the secondary seed liquid into a fermentation culture medium for high-density fermentation, wherein the inoculation amount is 3% (v/v), the culture condition is 35-37 ℃, and the culture is carried out for 24-48 h.
5) When the density of thalli in the fermentation solution reaches 10 8 ～10 9 CFU/mL, respectively collecting fermentation liquor; and respectively centrifuging the fermentation liquor to collect thalli.
6) After the thalli are collected, the thalli are resuspended by using a freeze-drying protective agent (the freeze-drying protective agent is prepared from the following components in percentage by weight: skimmed milk powder 15%, trehalose 6%, glycerol 4% and xylitol 1.5%) to give a resuspension.
7) And (3) freeze-drying the heavy suspension by adopting a vacuum freezing method to obtain lactobacillus acidophilus AD031 freeze-dried powder.
Example 5 preparation of probiotic powder
The addition amount of each component of the probiotic powder is as follows according to the addition amount of 5g per bag:
bifidobacterium bifidum BGN4 50 hundred million CFU/bag (counting live bacteria)
Bifidobacterium longum BORI 25 hundred million CFU/bag (in terms of viable count)
Lactobacillus casei IBS041 30 hundred million CFU/bag (counted by viable count)
Lactobacillus acidophilus AD031 25 hundred million CFU/bag (counting live bacteria)
Isomaltose hypgather 5 mg/bag
Fructo-oligosaccharide 8.2 mg/bag
Vitamin A34 mu g/bag
Vitamin B1 0.044 mg/bag
Vitamin B6 0.044 mg/bag
Vitamin B2 0.044 mg/bag
Nicotinic acid 0.66 mg/bag
Vitamin B12 0.132 mug/bag
Vitamin E0.36 mg/bag
Folic acid 12 mu g/bag
Vitamin C4.5 mg/bag
Iron 0.44 mg/bag
Collagen peptide 2.5 g/bag
The preparation method of the probiotic powder comprises the following steps:
1) Respectively taking 50 hundred million CFU of freeze-dried powder of bifidobacterium bifidum BGN4, 25 hundred million CFU of freeze-dried powder of bifidobacterium longum BORI, 30 hundred million CFU of freeze-dried powder of lactobacillus casei IBS041 and 25 hundred million CFU of freeze-dried powder of lactobacillus acidophilus AD031, and mixing.
2) Sequentially adding 5mg of isomaltooligosaccharide, 8.2mg of fructo-oligosaccharide, 34 mug of vitamin A, 0.044mg of vitamin B, 6.044 mg of vitamin B, 0.044mg of vitamin B, 0.66mg of nicotinic acid, 0.132 mug of vitamin B, 0.36mg of vitamin E, 12 mug of folic acid, 4.5mg of vitamin C, 0.44mg of iron and 2.5g of collagen peptide into the probiotic freeze-dried powder mixture, uniformly stirring, fully mixing, and subpackaging into bags to obtain the probiotic powder, wherein the bags are made of a food-grade PE packaging material with good sealing performance and safety, and the specification is 5g.
EXAMPLE 6 safety test
1. The safety of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041 and lactobacillus acidophilus AD031 is evaluated by evaluating hemolysis, mucin degradation, ammonia generation, biogenic amine generation, antimicrobial susceptibility analysis, transferability of antibiotic resistance, PCR data of antibiotic resistance genes, genome stability, whether virulence factors/pathogenic genes exist and other multi-aspect tests.
2. Test results
1) None of the four strains showed hemolytic activity nor mucin-degrading activity, and no ammonia production was observed.
2) The four strains do not produce 5-pentanediamine, histamine, tyramine, and produce small amounts of putrescine, similar to or less than other foods (e.g., spinach, tomato sauce, green beans, sauerkraut, and sausage).
3) The resistance (sensitivity) of the four strains to gentamicin and tetracycline is higher than the cut-off value of the European Food Safety Agency (EFSA).
4) In the PCR analysis study, no resistance gene of the strain was found.
5) The resistance of the four strains to antibiotics is not transferred by combining with gene fragments.
6) The entire genomic sequence of the four strains has been published in GenBank.
7) The four strains do not contain known toxin-producing genes and pathogenic genes.
Example 7 safety testing of probiotic powder
1. Detection basis and method
Safety detection is carried out on the probiotic powder according to standard methods such as pollutant limit GB 2762-2017 in food safety national standard food, food microbiology test (total colony count determination GB 4789.2-2016, escherichia coli count GB 4789.3-2016, salmonella test GB 4789.4-2016 and mould test GB 4789.15-2016).
2. The result of the detection
The probiotic powder for resisting obesity and slimming is prepared by adopting a freeze-dried microcapsule three-layer embedding technology, has beige powder, and has no visible foreign matters for normal vision, no agglomeration, no peculiar smell and no odor. And the detection results of the pollutants of lead and tin are inactive, and the total number of bacterial colonies, the detection results of escherichia coli, salmonella and mould are all passed.
EXAMPLE 8 specific cases
Case 1: patient male, 32 years old, complaining: due to frequent business project and irregular defecation cycle, the problems of abdominal distension and the like are also caused, the weight is obviously increased with the lapse of time, and the body is too fat. The probiotic powder prepared by the invention is eaten twice at a time, and the eating method is that the probiotic is directly poured into the mouth for dry eating, and the probiotic powder is taken within half an hour after meals and is eaten once in the morning and at night. After the food is continuously eaten for 6 months, regular defecation is improved within 1 year of follow-up visit, the weight is also reduced, and the meat of the belly and the face is obviously reduced under the condition of paying attention to diet.
Case 2: patient girl, 29 years old, complaining: however, the metabolic digestion is slow during the period of diet control and weight reduction exercise, so that knee cartilage tissue contusion occasionally occurs, and the exercise program is discontinuous. The probiotic powder prepared by the invention is eaten 2 bags at a time during contusion, and the eating method is that the probiotic is dissolved in warm boiled water at about 37 ℃, stirred until the probiotic is completely dissolved, and the probiotic is taken within half an hour after meals, and is eaten once in the morning and at night, and is eaten directly when people go out. After the probiotic powder is continuously eaten for 3 months and is followed up for 6 months, the metabolic digestion problem is improved, the recovery period of cartilage contusion is shortened, and the phenomenon of cartilage tissue contusion is not caused after the probiotic powder is continuously eaten during the body-building period.
Case 3: patient girl, 30 years old, complaint: often staying overnight, the weight is increased, the skin is aged roughly and obviously, wrinkles and fine lines are increased, and the skin is dark yellow and dull. The probiotic powder prepared by the invention is eaten 2 bags at a time, and the eating method is that the probiotic is dissolved in warm boiled water at about 37 ℃, stirred until the probiotic is completely dissolved, and the probiotic is taken within half an hour after meals, and is eaten once in the morning and at night, and is eaten directly when people go out. After the health food is continuously eaten for 6 months, the weight is reduced within 1 year of follow-up visit, spots and fine lines on the skin are reduced, and the face is ruddy and glossy.
Example 9 clinical trial
1. Study object
30 female patients of 25-35 years old are selected, and the phenomena of obesity and no obvious effect on body building are caused. 15 patients were assigned to the treatment group and the remaining 15 patients were assigned to the placebo group.
2. Method of treatment
The treatment group is 2 bags of probiotic powder prepared by the invention, and the placebo group is equivalent skimmed milk powder without probiotics, so that the treatment group is visually indistinguishable from the probiotic bag. Each patient should eat the food within 30 minutes after meals twice a day for 3 months. Defecation and weight changes during treatment were recorded.
3. Effect evaluation criterion
The results were evaluated by the defecation and weight change before and after the treatment period. The method has the following advantages: the weight loss or defecation is normal and regular or 2 problems are improved at the same time; and (4) invalidation: the conditions of 2 problems before and after treatment have no obvious improvement trend and change.
4. Statistical method
A paired t-test was performed to assess the quantitative changes in two groups of phenomena associated with weight obesity and no apparent effect on fitness: defecation and weight changes before and after the study period. When the p-value was <0.05, the results were considered statistically significant.
5. Test results
The results of 2 groups of effect evaluations are shown in Table 1.
TABLE 1 evaluation of the group effects
As can be seen from Table 1, the probiotic powder of the present invention has significant effects on the anti-obesity problem and significant improvement effects on defecation and weight change.
The invention provides a probiotic powder for resisting obesity and slimming and application thereof, wherein the probiotic powder consists of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041, lactobacillus acidophilus AD031, dual prebiotics, vitamins, iron and collagen peptide; can solve multiple problems of obese people, and is specifically embodied as follows: the probiotic powder has the effects of resisting obesity, slimming, protecting cartilage tissue of joint, resisting oxidation, tightening skin, and making skin glossy. Wherein, the matching use of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041 and lactobacillus acidophilus AD031 is verified in the aspect of helping the anti-obesity of human body; the protective effect of the cartilage tissue at the joints of the fitness and slimming crowd is verified; and can be applied to the problems of skin aging, more wrinkles, loose and dark yellow and the like. Therefore, the probiotic powder containing bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041 and lactobacillus acidophilus AD031 has great application prospect in promoting the anti-obesity and slimming performance of human bodies.
The foregoing is merely illustrative of the technical concepts and features of the present invention, which are intended to be known and practiced by those of ordinary skill in the art, and the scope of the present application is not limited by these specific embodiments. Various modifications and changes may occur to those skilled in the art. Any modification, equivalent change, equivalent replacement, improvement and the like made within the technical idea and principle of the present application should be included in the protection scope of the present application.
Claims (7)
1. The probiotic powder for resisting obesity and losing weight is characterized by consisting of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, lactobacillus casei IBS041, lactobacillus acidophilus AD031, dual prebiotics, vitamins, iron and collagen peptides; the bifidobacterium bifidum BGN4, the bifidobacterium longum BORI, the lactobacillus casei IBS041 and the lactobacillus acidophilus AD031 are main regulating components, and the dual prebiotics, the vitamins, the iron and the collagen peptide are auxiliary regulating components; wherein: the dual prebiotics comprise isomaltooligosaccharide and fructo-oligosaccharide, and the vitamins comprise vitamin A, vitamin B1, vitamin B6, vitamin B2, nicotinic acid, vitamin B12, vitamin E, folic acid and vitamin C.
2. The anti-obesity slimming probiotic powder according to claim 1, wherein the addition amount of each component of the probiotic powder is as follows according to the addition amount of 5g per bag:
bifidobacterium bifidum BGN4 50 hundred million CFU/bag (counting live bacteria)
Bifidobacterium longum BORI 25 hundred million CFU/bag (in terms of viable count)
Lactobacillus casei IBS041 30 hundred million CFU/bag (counted by viable count)
Lactobacillus acidophilus AD031 25 hundred million CFU/bag (counting according to viable count)
Isomaltose hypgather 5 mg/bag
Fructo-oligosaccharide 8.2 mg/bag
Vitamin A34 mu g/bag
Vitamin B1 0.044 mg/bag
Vitamin B6 0.044 mg/bag
Vitamin B2 0.044 mg/bag
Nicotinic acid 0.66 mg/bag
Vitamin B12 0.132 mug/bag
Vitamin E0.36 mg/bag
Folic acid 12 mu g/bag
Vitamin C4.5 mg/bag
Iron 0.44 mg/bag
Collagen peptide 2.5 g/bag
The preparation method of the probiotic powder comprises the following steps:
1) Preparation of freeze-dried powder
The protective agent is respectively mixed with the activated single pure bacterial strain and the bacterial liquid, and the mixture is poured into a container and placed in a vacuum freeze dryer to prepare 4 kinds of single probiotic freeze-dried bacterial powder.
2) Preparation of formula bacterial powder
Respectively taking 4 single probiotic freeze-dried powder according to the formula amount, mixing, sequentially adding isomaltooligosaccharide, fructo-oligosaccharide, vitamin A, vitamin B1, vitamin B6, vitamin B2, nicotinic acid, vitamin B12, vitamin E, folic acid, vitamin C, iron and collagen peptide according to the formula amount, mixing, uniformly stirring, and subpackaging to bags to obtain the probiotic powder.
3. The anti-obesity slimming probiotic powder according to claim 2, characterized in that the protective agent is prepared from the following components in percentage by weight: 15% of skimmed milk powder, 6% of trehalose, 4% of glycerol and 1.5% of xylitol.
4. The probiotic powder for resisting obesity and losing weight according to claim 2, wherein the probiotic powder packaging bag is made of food-grade PE packaging material with good sealing performance and safety.
5. The anti-obesity slimming probiotic powder according to claim 2, wherein said probiotic powder is administered in an amount of: the food is taken twice a day, and is drunk after being mixed with water at a temperature lower than 37 deg.C or directly taken, preferably within half an hour after meal.
6. The anti-obesity slimming probiotic powder according to claim 5, wherein the dietary recommendation of said probiotic powder is: during the period of taking the antibiotics, the antibiotics are firstly used, and the probiotic powder is used at intervals of 2-3 hours.
7. Use of a probiotic powder according to claim 1 or 2 for anti-obesity, slimming performance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210980670.9A CN115300605A (en) | 2022-08-16 | 2022-08-16 | Probiotic powder for resisting obesity and losing weight and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210980670.9A CN115300605A (en) | 2022-08-16 | 2022-08-16 | Probiotic powder for resisting obesity and losing weight and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115300605A true CN115300605A (en) | 2022-11-08 |
Family
ID=83862652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210980670.9A Pending CN115300605A (en) | 2022-08-16 | 2022-08-16 | Probiotic powder for resisting obesity and losing weight and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115300605A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119404998A (en) * | 2024-12-02 | 2025-02-11 | 中启铁君集团有限公司 | A kind of agkistrodon peptide composite probiotic solid beverage and preparation method |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140079676A1 (en) * | 2012-09-20 | 2014-03-20 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| KR20180065570A (en) * | 2016-12-08 | 2018-06-18 | 주식회사 비피도 | Composition comprising bifidobacteria for preventing or treating of fatty liver |
| CN108294318A (en) * | 2018-03-02 | 2018-07-20 | 武汉华康臣生物科技有限公司 | It is a kind of weight-reducing and control body weight functional food |
| KR20180102923A (en) * | 2017-03-08 | 2018-09-18 | 서울대학교산학협력단 | Composition comprising bifidobacteria for preventing or treating of obesity |
| AU2020101019A4 (en) * | 2020-03-06 | 2020-07-23 | Warchalowski, Agnieszka DR | A provider-supervised and individualised method for weight management that includes nutritional compositions and therapeutic dietary techniques to improve the key physiological processes involved in weight management, namely gut microbial composition, gut wall integrity, immune function, mitochondrial function, nutrient status, detoxification, appetite-regulation, metabolic hormones, neurotransmitter synthesis and neurogenesis . |
| US20210196767A1 (en) * | 2018-03-29 | 2021-07-01 | Morinaga Milk Industry Co., Ltd. | Obesity treatment using probiotics, composition for reducing body fat, and composition for reducing waist circumference |
| US20220062368A1 (en) * | 2018-03-20 | 2022-03-03 | Exerkine Corporation | Weight Management Composition |
| CN114832021A (en) * | 2022-05-17 | 2022-08-02 | 比菲德(北京)生物科技有限公司 | Probiotic powder containing human homologous strains and application thereof |
-
2022
- 2022-08-16 CN CN202210980670.9A patent/CN115300605A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140079676A1 (en) * | 2012-09-20 | 2014-03-20 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| KR20180065570A (en) * | 2016-12-08 | 2018-06-18 | 주식회사 비피도 | Composition comprising bifidobacteria for preventing or treating of fatty liver |
| KR20180102923A (en) * | 2017-03-08 | 2018-09-18 | 서울대학교산학협력단 | Composition comprising bifidobacteria for preventing or treating of obesity |
| CN108294318A (en) * | 2018-03-02 | 2018-07-20 | 武汉华康臣生物科技有限公司 | It is a kind of weight-reducing and control body weight functional food |
| US20220062368A1 (en) * | 2018-03-20 | 2022-03-03 | Exerkine Corporation | Weight Management Composition |
| US20210196767A1 (en) * | 2018-03-29 | 2021-07-01 | Morinaga Milk Industry Co., Ltd. | Obesity treatment using probiotics, composition for reducing body fat, and composition for reducing waist circumference |
| AU2020101019A4 (en) * | 2020-03-06 | 2020-07-23 | Warchalowski, Agnieszka DR | A provider-supervised and individualised method for weight management that includes nutritional compositions and therapeutic dietary techniques to improve the key physiological processes involved in weight management, namely gut microbial composition, gut wall integrity, immune function, mitochondrial function, nutrient status, detoxification, appetite-regulation, metabolic hormones, neurotransmitter synthesis and neurogenesis . |
| CN114832021A (en) * | 2022-05-17 | 2022-08-02 | 比菲德(北京)生物科技有限公司 | Probiotic powder containing human homologous strains and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| S NOBAEK等: "Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome", AM J GASTROENTEROL, vol. 95, no. 5, pages 1231 - 1238, XP009042093, DOI: 10.1111/j.1572-0241.2000.02015.x * |
| ZHIPENG LI等: "Anti-obese effects of two Lactobacilli and two Bifidobacteria on ICR mice fed on a high fat diet", BIOCHEM BIOPHYS RES COMMUN, vol. 480, no. 2, pages 222 - 227 * |
| 徐光来编: "《海洋生物活性肽的研究与产业化》", 杭州：浙江工商大学出版社, pages: 161 - 174 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119404998A (en) * | 2024-12-02 | 2025-02-11 | 中启铁君集团有限公司 | A kind of agkistrodon peptide composite probiotic solid beverage and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4011532B2 (en) | Bifidobacteria and preparations containing the same | |
| AU2006253007B2 (en) | Feline probiotic Bifidobacteria | |
| AU2010213009B2 (en) | Lactobacillus rhamnosus NCC4007, a probiotic mixture and weight control | |
| ES2540569T3 (en) | Bifidobacteria producing folic acid, food composition and use of said bifidobacteria | |
| US9962415B2 (en) | Lachnospiraceae in the gut microbiota and association with body weight | |
| US20100166721A1 (en) | Probotic compositions and uses thereof | |
| TWI594758B (en) | Composition comprising bifidobacteria,processes for the preparation thereof and uses thereof | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| PL192776B1 (en) | Fodder for horses, bacterial strain lactobacillus plantarum ji:1, lactobacillus species ac:3, and application of strain lactobacillus plantarum ji:1 | |
| WO2018003900A1 (en) | Composition for use in improvement of nutritional state | |
| CN110959867A (en) | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof | |
| CN116746683A (en) | Bifidobacterium animalis subsp. lactis BAL-28, which prevents indigestion and flatulence and promotes absorption, and its fermentation products, bacterial flora CW and applications | |
| CN118575952A (en) | Probiotic composition for improving intestinal flora balance, preparation method and application thereof | |
| CN117617506A (en) | Application of Bifidobacterium breve strain grx05 in relieving constipation and regulating intestinal flora | |
| JP2003252770A (en) | Agent for prevention, improvement and treatment of diabetic complication | |
| CN115300605A (en) | Probiotic powder for resisting obesity and losing weight and application thereof | |
| JP2012180288A (en) | Antibacterial agent | |
| CN111035661A (en) | Application of lactobacillus plantarum | |
| CN110897166B (en) | Edible composition containing probiotics and casein phosphopeptide with digestion promoting effect | |
| US20230248787A1 (en) | Probiotic strain selected by targeted in vivo enrichment to aid with healthy lactose digestion | |
| CN115466687B (en) | Composition for reducing body fat content and body weight and application thereof | |
| CN114832021A (en) | Probiotic powder containing human homologous strains and application thereof | |
| CN113186118B (en) | A compound probiotic preparation for improving the production performance of sows and its preparation method | |
| CN115025135A (en) | Probiotic powder for relieving female private infection and application thereof | |
| CN114984061A (en) | Probiotic powder for relieving autoimmune diseases and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221108 |
|
| RJ01 | Rejection of invention patent application after publication |